Ullah W, Ali Z, Sadiq U, et al. - This study was undertaken to ascertain the relative merits of one agent over the other. Multiple databases were queried to identify relevant randomized control trials (RCTs) and observational cohort studies (OCS). Researchers applied random-effects model to estimate an unadjusted odds ratio (OR) for major cardiovascular events (MACE) and its components. A total of 27 (7 RCTs, 20 OCS) studies comprising 118,266 (prasugrel 62,716, ticagrelor 51,196) patients were included. prasugrel might have lower odds of MACCE and mortality at 30-days. However, there was no difference in the safety and efficacy endpoints of two drugs at 1-year. The observed transient prasugrel related mortality benefits were subject to the bias of nonrandomized assignment.